FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385702559> ?p ?o ?g. }

• W4385702559 endingPage "e70124b5" @default.
• W4385702559 startingPage "e70124b5" @default.
• W4385702559 abstract "Topic: 6. Chronic lymphocytic leukemia and related disorders - Clinical Background: Zanubrutinib (320 mg QD or 160 mg BID) is a next-generation irreversible Bruton tyrosine kinase (BTK) inhibitor approved in various countries for the treatment of relapsed/refractory (R/R) mantle cell lymphoma (MCL), Waldenström macroglobulinemia (WM), marginal zone lymphoma (MZL), and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). While both QD and BID doses were studied in select phase 1 and 2 zanubrutinib trials, only the BID dose has been used in pivotal clinical studies to date. Thus, a summary of clinical data and analyses between the 2 schedules across various B-cell malignancies is of interest. Aims: We aimed to conduct a comparative summary of safety and efficacy data between the QD and BID regimens in patients with various B-cell malignancies. In addition, exposure-response (E-R) analyses for safety and efficacy endpoints were conducted to bridge the QD and BID regimen. Methods: Patients from 5 studies were included in the analysis (monotherapy: BGB-3111-AU-003, BGB-3111-215, BGB-3111-216, BGB-3111-1002; combination with obinutuzumab: BGB-3111-GA-101). The following safety and efficacy endpoints were analyzed: adverse events of special interest (AESI), disease response (overall response rate [ORR], complete response [CR] rate or complete metabolic response, and rate of very good partial response [VGPR] or better for WM). The incidence and severity of AESI were prespecified based on the known toxicity for the BTK inhibitor class, including infections, bleeding, hypertension, atrial fibrillation/flutter, and peripheral blood cytopenias. For the E-R analyses, a population pharmacokinetic (PK) model predicted individual area under the curve (AUC), peak concentration (Cmax), and minimum observed concentration (Cmin) values, which were merged with corresponding safety or efficacy data. Then, exposure-efficacy and safety relationships were assessed (eg, probability of response plots and logistic regression model) in patients with MCL, WM, MZL, CLL/SLL and follicular lymphoma (FL) from the 5 zanubrutinib studies described. Results: A total of 216 patients with various B-cell malignancies receiving zanubrutinib 320 mg QD were identified across 5 studies. There are no marked differences in objective responses observed using QD or BID doses in patients across various indications; while there was a numerical difference, the confidence intervals were overlapping (a subset of efficacy evaluable population, with N≥5 in each indication is summarized [Table]). Similar to the previous report (Ou et al. Leuk Lymphoma 2021), comparable safety profiles were observed with both dosing schedules. In 278 patients receiving zanubrutinib BID vs 95 receiving zanubrutinib QD from the BGB-3111-AU-003 study, respectively, rates of ≥1 AE leading to treatment discontinuation (11.2% vs 8.4), grade ≥3 hemorrhage (4.0% vs 3.2%), grade ≥3 hypertension (4.0% vs 2.1%), and grade ≥3 atrial fibrillation/flutter (1.4% vs 1.1%) were comparable. There were no evident E-R relationships between PK exposure (AUC, Cmax, or Cmin) and efficacy endpoints or the probability of having an AESI across indications. Overall, the E-R analysis showed that ORR and adverse event rate was not impacted by Cmax or Cmin differences between the QD and BID regimens that have the same total daily dose and AUC. Summary/Conclusion: Both 320 mg QD and 160 mg BID are safe and effective regimens with high rates of objective response in patients with various B-cell malignancies. Comparison of the ORR between QD and BID dosing did not indicate advantage of either regimen.Keywords: Non-Hodgkin’s lymphoma, Tyrosine kinase inhibitor, Pharmacokinetic" @default.
• W4385702559 created "2023-08-10" @default.
• W4385702559 creator A5000959540 @default.
• W4385702559 creator A5001949103 @default.
• W4385702559 creator A5007310385 @default.
• W4385702559 creator A5013007045 @default.
• W4385702559 creator A5014942120 @default.
• W4385702559 creator A5019857907 @default.
• W4385702559 creator A5019979393 @default.
• W4385702559 creator A5034517642 @default.
• W4385702559 creator A5054424938 @default.
• W4385702559 creator A5055770139 @default.
• W4385702559 creator A5057839067 @default.
• W4385702559 creator A5062534813 @default.
• W4385702559 creator A5063691595 @default.
• W4385702559 creator A5077247997 @default.
• W4385702559 creator A5082805908 @default.
• W4385702559 date "2023-08-01" @default.
• W4385702559 modified "2023-10-01" @default.
• W4385702559 title "PB1926: EFFICACY AND SAFETY OF ONCE DAILY (QD) VS TWICE DAILY (BID) ZANUBRUTINIB FOR PATIENTS WITH VARIOUS B-CELL MALIGNANCIES: A COMPARATIVE SUMMARY OF CLINICAL DATA AND EXPOSURE-RESPONSE ANALYSES" @default.
• W4385702559 doi "https://doi.org/10.1097/01.hs9.0000974528.70124.b5" @default.
• W4385702559 hasPublicationYear "2023" @default.
• W4385702559 type Work @default.
• W4385702559 citedByCount "0" @default.
• W4385702559 crossrefType "journal-article" @default.
• W4385702559 hasAuthorship W4385702559A5000959540 @default.
• W4385702559 hasAuthorship W4385702559A5001949103 @default.
• W4385702559 hasAuthorship W4385702559A5007310385 @default.
• W4385702559 hasAuthorship W4385702559A5013007045 @default.
• W4385702559 hasAuthorship W4385702559A5014942120 @default.
• W4385702559 hasAuthorship W4385702559A5019857907 @default.
• W4385702559 hasAuthorship W4385702559A5019979393 @default.
• W4385702559 hasAuthorship W4385702559A5034517642 @default.
• W4385702559 hasAuthorship W4385702559A5054424938 @default.
• W4385702559 hasAuthorship W4385702559A5055770139 @default.
• W4385702559 hasAuthorship W4385702559A5057839067 @default.
• W4385702559 hasAuthorship W4385702559A5062534813 @default.
• W4385702559 hasAuthorship W4385702559A5063691595 @default.
• W4385702559 hasAuthorship W4385702559A5077247997 @default.
• W4385702559 hasAuthorship W4385702559A5082805908 @default.
• W4385702559 hasBestOaLocation W43857025591 @default.
• W4385702559 hasConcept C126322002 @default.
• W4385702559 hasConcept C143998085 @default.
• W4385702559 hasConcept C197934379 @default.
• W4385702559 hasConcept C2777525834 @default.
• W4385702559 hasConcept C2777607594 @default.
• W4385702559 hasConcept C2777938653 @default.
• W4385702559 hasConcept C2778461978 @default.
• W4385702559 hasConcept C2778570526 @default.
• W4385702559 hasConcept C2779338263 @default.
• W4385702559 hasConcept C2779878957 @default.
• W4385702559 hasConcept C2781038049 @default.
• W4385702559 hasConcept C535046627 @default.
• W4385702559 hasConcept C71924100 @default.
• W4385702559 hasConcept C90924648 @default.
• W4385702559 hasConceptScore W4385702559C126322002 @default.
• W4385702559 hasConceptScore W4385702559C143998085 @default.
• W4385702559 hasConceptScore W4385702559C197934379 @default.
• W4385702559 hasConceptScore W4385702559C2777525834 @default.
• W4385702559 hasConceptScore W4385702559C2777607594 @default.
• W4385702559 hasConceptScore W4385702559C2777938653 @default.
• W4385702559 hasConceptScore W4385702559C2778461978 @default.
• W4385702559 hasConceptScore W4385702559C2778570526 @default.
• W4385702559 hasConceptScore W4385702559C2779338263 @default.
• W4385702559 hasConceptScore W4385702559C2779878957 @default.
• W4385702559 hasConceptScore W4385702559C2781038049 @default.
• W4385702559 hasConceptScore W4385702559C535046627 @default.
• W4385702559 hasConceptScore W4385702559C71924100 @default.
• W4385702559 hasConceptScore W4385702559C90924648 @default.
• W4385702559 hasIssue "S3" @default.
• W4385702559 hasLocation W43857025591 @default.
• W4385702559 hasLocation W43857025592 @default.
• W4385702559 hasOpenAccess W4385702559 @default.
• W4385702559 hasPrimaryLocation W43857025591 @default.
• W4385702559 hasRelatedWork W1865071181 @default.
• W4385702559 hasRelatedWork W2095408122 @default.
• W4385702559 hasRelatedWork W2281396854 @default.
• W4385702559 hasRelatedWork W2384638857 @default.
• W4385702559 hasRelatedWork W2411767449 @default.
• W4385702559 hasRelatedWork W2419308557 @default.
• W4385702559 hasRelatedWork W2898859429 @default.
• W4385702559 hasRelatedWork W2917422129 @default.
• W4385702559 hasRelatedWork W4318754427 @default.
• W4385702559 hasRelatedWork W4323295307 @default.
• W4385702559 hasVolume "7" @default.
• W4385702559 isParatext "false" @default.
• W4385702559 isRetracted "false" @default.
• W4385702559 workType "article" @default.